80%Confidence
0Views
FDASource
2026-04-20Date
Summary
Fresenius Kabi's recall involving a BD-distributed product expands the impact to a major medical device company. This collaboration risk could lead BD to reconsider its supplier relationships.
Actionable: Assess BD's supply chain resilience and potential for reputational damage from association with recalled products.
AI Confidence: 80%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL in a Single Dose freeflex bag, Rx only, BD Beckton, Dickson and Company, 1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now